Ultragenyx Stock Investor Sentiment

RARE Stock  USD 39.34  0.09  0.23%   
About 66% of Ultragenyx's investor base is looking to short. The analysis of the overall investor sentiment regarding Ultragenyx suggests that many traders are alarmed. The current market sentiment, together with Ultragenyx's historical and current headlines, can help investors time the market. In addition, many technical investors use Ultragenyx stock news signals to limit their universe of possible portfolio assets.

Comfort Level 34

 Alarmed

 
Panic
 
Confidence
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Ultragenyx's input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Ultragenyx.

Ultragenyx Historical Sentiment

Although Ultragenyx's investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding Ultragenyx, such as negative comments on social media and news outlets, may cause fear in the market and push Ultragenyx's investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of Ultragenyx.
  

Ultragenyx Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Ultragenyx can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Ultragenyx Historical Investor Sentiment

Investor biases related to Ultragenyx's public news can be used to forecast risks associated with an investment in Ultragenyx. The trend in average sentiment can be used to explain how an investor holding Ultragenyx can time the market purely based on public headlines and social activities around Ultragenyx. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Ultragenyx's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Ultragenyx and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Ultragenyx news discussions. The higher the estimate score, the more favorable the investor's outlook on Ultragenyx.

Ultragenyx Maximum Pain Price Across June 20th 2025 Option Contracts

Ultragenyx's options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Ultragenyx close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Ultragenyx's options.
2 days ago at www.macroaxis.com         
Acquisition by Crombez Eric of 14971 shares of Ultragenyx subject to Rule 16b-3
Macroaxis News
3 days ago at www.macroaxis.com         
Disposition of 7500 shares by Fust Matthew K of Ultragenyx at 50.88 subject to Rule 16b-3
Macroaxis News
few days ago at simplywall.st         
Have Insiders Sold Ultragenyx Pharmaceutical Shares Recently?
Simply Wall St News at Macroaxis
few days ago at globenewswire.com         
Kaerus Bioscience Successfully Completes Phase 1 Trial and Demonstrates Proof of Mechanism with its ...
Macroaxis News: globenewswire.com
few days ago at news.google.com         
Ultragenyx CFO Makes a Bold Stock Move - TipRanks
Google News at Macroaxis
over a week ago at www.macroaxis.com         
Disposition of 584 shares by Sanders Corazon D. of Ultragenyx at 40.98 subject to Rule 16b-3
Macroaxis News
over a week ago at globenewswire.com         
2024 Wilson Disease Pipeline Market Analysis Report Featuring Alexion Pharmaceuticals, Inc., Vivet T...
Macroaxis News: globenewswire.com
over a week ago at thelincolnianonline.com         
Candriam S.C.A. Sells 38,835 Shares of Ultragenyx Pharmaceutical Inc.
news
over a week ago at finance.yahoo.com         
Gene Therapy Market Global Forecast to 2032 Biopharma Giants Lead Gene Therapy Market Expansion Late...
Yahoo News
over a week ago at thelincolnianonline.com         
Ultragenyx Pharmaceutical Inc. EVP Sells 128,211.20 in Stock
news
over a week ago at thelincolnianonline.com         
Disposition of 1785 shares by Howard Horn of Ultragenyx at 40.4 subject to Rule 16b-3
news
over a week ago at thelincolnianonline.com         
John Richard Pinion Sells 14,4 Shares of Ultragenyx Pharmaceutical Inc. Stock
news
over a week ago at finance.yahoo.com         
Global Genome Editing Market to Grow Rapidly at a CAGR 13 percent by 2032 DelveInsight
Yahoo News
over a week ago at finance.yahoo.com         
Global Cell and Gene Therapy Manufacturing Market to Reach USD 10 Billion by 2032 DelveInsight
Yahoo News
over a week ago at www.macroaxis.com         
Acquisition by Howard Horn of 15653 shares of Ultragenyx subject to Rule 16b-3
Macroaxis News
Far too much social signal, news, headlines, and media speculation about Ultragenyx that are available to investors today. That information is available publicly through Ultragenyx media outlets and privately through word of mouth or via Ultragenyx internal channels. However, regardless of the origin, that massive amount of Ultragenyx data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Ultragenyx news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Ultragenyx relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Ultragenyx's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Ultragenyx alpha.

Ultragenyx Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Disposition of 11727 shares by Kakkis Emil D of Ultragenyx at 42.23 subject to Rule 16b-3
12/30/2024
2
European Commission Extends the Approval of Evkeeza to Children as Young as 6-months Old with Homozygous Familial Hypercholesterolemia
01/06/2025
3
Disposition of 9806 shares by Parschauer Karah Herdman of Ultragenyx at 45.0 subject to Rule 16b-3
01/21/2025
4
Rhythm Pharmaceuticals Soars 5.5 percent Is Further Upside Left in the Stock
01/22/2025
5
Ultragenyx Reports Q4 Loss, Tops Revenue Estimates
02/13/2025
6
Ultragenyx Announces FDA Acceptance and Priority Review of the Biologics License Application for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A
02/18/2025
7
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635
02/19/2025
8
Ultragenyx Pharmaceutical Inc Grants Restricted Stock Units to New Employees
02/21/2025
9
Disposition of 760 shares by Parschauer Karah Herdman of Ultragenyx at 42.75 subject to Rule 16b-3
02/27/2025
10
Disposition of 141 shares by Theodore Huizenga of Ultragenyx at 42.92 subject to Rule 16b-3
03/03/2025
11
Acquisition by Howard Horn of 15653 shares of Ultragenyx subject to Rule 16b-3
03/04/2025
12
Disposition of 1785 shares by Howard Horn of Ultragenyx at 40.4 subject to Rule 16b-3
03/06/2025
13
2024 Wilson Disease Pipeline Market Analysis Report Featuring Alexion Pharmaceuticals, Inc., Vivet Therapeutics SAS, Ultragenyx Pharmaceutical and Nobelpharma
03/07/2025
14
Have Insiders Sold Ultragenyx Pharmaceutical Shares Recently
03/11/2025
15
Disposition of 7500 shares by Fust Matthew K of Ultragenyx at 50.88 subject to Rule 16b-3
03/13/2025
16
Acquisition by Crombez Eric of 14971 shares of Ultragenyx subject to Rule 16b-3
03/14/2025

Complementary Tools for Ultragenyx Stock analysis

When running Ultragenyx's price analysis, check to measure Ultragenyx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ultragenyx is operating at the current time. Most of Ultragenyx's value examination focuses on studying past and present price action to predict the probability of Ultragenyx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ultragenyx's price. Additionally, you may evaluate how the addition of Ultragenyx to your portfolios can decrease your overall portfolio volatility.
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators